An Exploratory, Open-Label Study of Vedolizumab (Anti-alpha4beta7 Antibody) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption

Trial Profile

An Exploratory, Open-Label Study of Vedolizumab (Anti-alpha4beta7 Antibody) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Apr 2017 Planned number of patients changed from 20 to 40.
    • 29 Jul 2016 Status changed from not yet recruiting to recruiting.
    • 09 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top